Phenotypes associated with this allele

• Allele Symbol: Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps
• Allele Name: transgene insertion, David M Spencer
• Allele ID: MGI:5633960
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0 Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0	involves: FVB/N	MGI:5633987
tg2	Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0	involves: FVB/N	MGI:5633962

Genotype
MGI:5633987

cx1

• Allelic Composition: Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0; Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased prostate gland adenocarcinoma incidence ( J:206727 )

♂ • mice develop adenocarcinoma by 24 weeks after treatment with a chemical inducer of dimerization, AP20187 and continue to progress, showing tissues containing 50% sarcomatoid carcinoma by 40 weeks of age

♂ • tumors show heterogeneous, invasive hyperchromatic epithelial cells and loss of the basal cell layer

♂ • tumors are surrounded by fibroblastic reactive stroma that is very collagen-rich

increased spindle cell carcinoma incidence ( J:206727 )

♂ • by 40 weeks of AP20187 treatment, mice show prostate tissues containing 50% sarcomatoid carcinoma

reproductive system

increased prostate gland adenocarcinoma incidence ( J:206727 )

♂ • mice develop adenocarcinoma by 24 weeks after treatment with a chemical inducer of dimerization, AP20187 and continue to progress, showing tissues containing 50% sarcomatoid carcinoma by 40 weeks of age

♂ • tumors show heterogeneous, invasive hyperchromatic epithelial cells and loss of the basal cell layer

♂ • tumors are surrounded by fibroblastic reactive stroma that is very collagen-rich

endocrine/exocrine glands

increased prostate gland adenocarcinoma incidence ( J:206727 )

♂ • mice develop adenocarcinoma by 24 weeks after treatment with a chemical inducer of dimerization, AP20187 and continue to progress, showing tissues containing 50% sarcomatoid carcinoma by 40 weeks of age

♂ • tumors show heterogeneous, invasive hyperchromatic epithelial cells and loss of the basal cell layer

♂ • tumors are surrounded by fibroblastic reactive stroma that is very collagen-rich

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
prostate cancer		DOID:10283	OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959	J:206727

Genotype
MGI:5633962

tg2

• Allelic Composition: Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
• Genetic Background: involves: FVB/N

endocrine/exocrine glands

prostate gland hyperplasia ( J:184212 , J:206727 )

♂ • treatment with with a chemical inducer of dimerization, AP20187, for up to 20 weeks results in a modest hyperproliferation of prostate epithelial cells, high proliferative rates in both ventral and dorsal lobes, development of luminal hyperplasia, and modest stromal thickening (J:184212)

♂ • treatment with AP20187 beyond 20 weeks results in more prominent hyperproliferation in the ventral and dorsal prostate lobes and acinar disorganization (J:184212)

♂ (J:206727)

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)

reproductive system

prostate gland hyperplasia ( J:184212 , J:206727 )

♂ • treatment with with a chemical inducer of dimerization, AP20187, for up to 20 weeks results in a modest hyperproliferation of prostate epithelial cells, high proliferative rates in both ventral and dorsal lobes, development of luminal hyperplasia, and modest stromal thickening (J:184212)

♂ • treatment with AP20187 beyond 20 weeks results in more prominent hyperproliferation in the ventral and dorsal prostate lobes and acinar disorganization (J:184212)

♂ (J:206727)

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)

neoplasm

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)